Biggest News Aggregation in the World
📰 Research Early Development News

Page 2 - Research Early Development News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Research Early Development. Real-time updates on events, politics, business and more.

Investegate |https://immatics.com/ Announcements | https://immatics.com/: Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

Investegate announcements from https://immatics.com/, Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
New York United States Harpreet Singh Rupert Vessey Anja Heuer Bristol Myers Squibbto

BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology

BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology - read this article along with other careers information, tips and advice on BioSpace
United States Rupert Vessey Neil Kumar Bristol Myers Squibb Research Early Development Bristol Myers Squibb Company

Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb

/PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly") today announced the achievement of a Phase 1 clinical development milestone for the...
Rupert Vessey Bristol Myers Squibb Anne Deconinck Research Early Development Therapeutics Inc Prnewswire Dragonfly Therapeutics Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Dragonfly Therapeutics, Inc.: Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb

Dragonfly receives a milestone payment from Bristol Myers Squibb for progression of its Phase 1 DF6002-001 study with a PK profile and peripheral PD consistent with preclinical models WALTHAM
Rupert Vessey Bristol Myers Squibb Anne Deconinck Research Early Development Prnewswire Dragonfly Therapeutics Inc Drug Administration

Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb

/PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly") today announced the achievement of a Phase 1 clinical development milestone for the...
Rupert Vessey Bristol Myers Squibb Anne Deconinck Research Early Development Therapeutics Inc Prnewswire Dragonfly Therapeutics Inc

Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-d

Collaboration brings together Century’s industry leading iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug developmentFirst two programs include a program in acute myeloid leukemia and a program in multiple myeloma, which could incorporate either th...
United States Lalo Flores Nina Goworek Joshuar Mansbach Rupert Vessey Elizabeth Krutoholow

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science